Dr Wei speaks with ecancertv at ASH 2016 about treating AML in elderly patients with venetoclax, a Bcl-2 inhibitor, and cytarabine (ara-c).

He describes patient outcomes following venetoclax 600mg and low-dose cytarabine, with high response and complete remission rates.

Dr Wei summarises subgroup analysis, and outlines how results maturing in the future will better inform any changes to practice.

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.